Please note that this product was withdrawn from the Community Register of designated Orphan Medicinal Products in March 2015 on request of the Sponsor.
On 14 February 2003, orphan designation (EU/3/03/137) was granted by the European Commission to Amersham plc, U.K., for tositumomab for the treatment of follicular lymphoma.
The sponsorship was transferred to GlaxoSmithKline Research & Development Limited, United Kingdom, in August 2005.
For a list of the administrative updates to this public summary of opinion please refer to the PDF document below.
Treatment of follicular lymphoma
|Orphan designation status||
|EU designation number||
|Date of designation||
GlaxoSmithKline Research & Development Ltd
1-3 Iron Bridge Road
Stockley Park West
Middlesex UB11 1BT
Tel. +44 (0)20 8990 3879
Fax +44 (0)20 8990 3511
Documents related to this orphan designation evaluation
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.
EU register of orphan medicines
The list of medicines that have received an orphan designation in the EU is available on the European Commission's website: